Bruce C Cozadd

Director Bruce C Cozadd sold 6,000 shares of JAZZ at $235.12 under scheduled 10b5-1 plan, retains 372.7K shares.

Bruce C Cozadd, a Director of Jazz Pharmaceuticals, sold 6,000 shares (6.0K shares) for $1,410,720.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-26, meaning the sale was scheduled rather than discretionary. His post-transaction holdings of 372.7K shares represent a -1.6% reduction from pre-transaction holdings of 378.7K shares, a modest portfolio adjustment. His prior sales at JAZZ show mixed outcomes: three April 2026 sales each yielded 30-day gains of 5.7%-6.6% followed by 90-day gains of 17.9%-18.9%, while two March 2026 sales had near-flat 30-day performance (0.1%-0.5%) before 90-day gains of 24.6%-25.0%. The current market context shows JAZZ trading at $230.93, down 5.1% from its 52-week high of $243.32, while the broader market has rallied +25.8% over 90 days and +11.0% over 30 days.

Director Bruce C Cozadd sold 6,000 shares of JAZZ at $203.33 under pre-arranged 10b5-1 plan; holds 378.7K shares post-sale.

Director Bruce C Cozadd sold 6,000 shares (a net change of -1.6% vs pre-transaction holdings of 384.7K shares) at $203.33 on 2026-05-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-26, making this a scheduled, non-discretionary transaction. His cross-ticker track record shows 16 prior sells with an average 90-day return of +0.4%, while his five prior trades at JAZZ have been entirely sells, with measurable same-ticker outcomes ranging from +0.1% to +24.6% over 90 days. JAZZ shares currently trade at $230.56, up 29.1% over the past 90 days and near the 52-week high of $243.32, though the company carries an elevated P/E of 490.55 and was unprofitable on a full-year basis despite recent quarterly profitability of $293.1M on $1.1B in revenue. The scheduled nature of the transaction limits inference about timing discretion.

Director Bruce Cozadd sold 6,000 shares at $190.50 avg; stock now $186.95; prior JAZZ trades showed 100% well-timed at 90 days

Director Bruce Cozadd executed 3 separate sales totaling 6,000 shares for $1,143,010.30 on 2026-04-01 at prices ranging from $190.22 to $191.74, representing a 1.5% reduction in his 390.7K pre-transaction holdings. Jazz Pharmaceuticals trades 5.0% below its 52-week high of $196.83, and Cozadd's cross-ticker track record shows a 100% well-timed rate on his 12 prior open-market sells (90-day average return -7.6%), though at Jazz specifically his 2 prior measurable 90-day outcomes both showed negative returns (-3.0% and -2.4%). The current price of $186.95 is 1.9% below Cozadd's blended average transaction price, and the company reported full-year net income was negative despite latest-quarter earnings of $251.4M on $1.1B revenue. The filing itself carries no execution plan flag, leaving timing as a property of the trade, though the modest 1.5% position reduction and continued ownership of 384.7K shares suggests no wholesale exit conviction.

Director COZADD sells 6,000 shares at $186.09–$187.84 for $1.1M; retains 405.8K shares post-transaction

COZADD BRUCE C, a Director, executed 3 separate sales totaling 6,000 shares for $1,118,613.48 at blended average price $186.44 on 2026-03-03. Post-transaction holdings of 405.8K shares represent a -1.5% reduction and still constitute a substantial position. His same-ticker history at JAZZ shows 5 prior sells (all on 2025-11-18 and 2025-11-26), with 100% of those prior trades resulting in negative 90-day returns, indicating consistent execution before subsequent stock declines. Current price of $188.69 is -4.1% from the 52-week high of $196.83 and up 12.8% over the 30-day period, placing this sale in a recent uptrend. The company posted $1.1B in latest quarterly revenue and a full-year net income that was negative over its most recent fiscal year, establishing a mixed financial backdrop against which to assess insider motivation.

Jazz Pharmaceuticals director Bruce Cozadd sells 77,500 shares for $13.8M at $177.81 avg; holds 393.3K shares post-sale

Cozadd executed 4 separate sales totaling 77,500 shares for $13,780,337.23 on 2025-11-26, reducing his Jazz Pharmaceuticals holdings by 16.5% to 393.3K shares. The sales occurred just 8 days after 4 sales on 2025-11-18, forming a two-week pattern of systematic liquidation. Against the company's strong fundamentals (P/E: 19.00, revenue growth +6.1%, net income $251.4M), this concentrated director sale deserves attention. His cross-ticker track record shows a 90-day well-timed rate of 100.00%, though at Jazz specifically his most recent measurable result (2025-03-03 sale) showed a 90-day return of -25.1%, indicating the stock did decline after that prior sale.

Director Bruce Cozadd sells 18,000 shares of JAZZ at $180.09–$182.60 for $3.3M, reducing holdings 4.4% post-transaction.

Bruce Cozadd executed 4 separate sales totaling 18,000 shares for $3,259,537.82 on 2025-11-18, with a blended average price of $181.09. The stock has since declined 2.6% from its 52-week high of $180.52, falling to a current price of $175.74. Notably, Cozadd's cross-ticker track record shows a 100.00% well-timed rate on prior sells, with his only prior JAZZ sale on 2025-03-03 recording a 90-day return of -25.1%, consistent with well-timed exit pattern. The stock has appreciated 27.8% over 30 days and 42.8% over 90 days heading into this transaction, yet Cozadd sold near the recent high, continuing a demonstrated pattern of selling into strength. While post-sale price action remains limited, the timing into local peaks and the director's historical execution warrant attention to whether this signals anticipated headwinds or reflects liquidity needs independent of forward fundamentals.

JAZZ CEO Cozadd sold 6,500 shares at $144.25 on 2025-03-03; retains 464,058 shares

COZADD BRUCE C, Chairman & CEO of Jazz Pharmaceuticals, sold 6,500 shares at $144.25, representing a 1.4% reduction in his post-transaction holdings of 464,058 shares. The sale occurred near the 52-week high of $144.17, with the stock currently trading at $140.22. The company shows solid fundamentals with $1.1B latest quarterly revenue, $215.1M net income, and a P/E of 13.99. The modest sale size relative to his substantial remaining position (464,058 shares) and the lack of pattern data in this filing do not suggest material portfolio repositioning. The transaction's proximity to all-time highs warrants routine monitoring but does not indicate material internal concerns given the CEO's continued substantial stake and the company's stable financial performance.